Back to top
more

AC Immune SA (ACIU)

(Real Time Quote from BATS)

$4.97 USD

4.97
17,705

-0.12 (-2.36%)

Updated May 20, 2019 10:26 AM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.08%
18.07%
9.73%
5.25%
2.19%
10.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | A Growth | A Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ACIU

Zacks Equity Research

AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACIU

Zacks Equity Research

Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003

Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.

ABBV LLY ACIU ALEC

Zacks Equity Research

Lilly (LLY) Signs New Immunology Deal With Private Biotech

Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

LLY SNY ADRO ACIU

Zacks Equity Research

What Makes AC Immune (ACIU) a New Buy Stock

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACIU

Zacks Equity Research

Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?

Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.

BIO ADRO ACIU APTO

Zacks Equity Research

Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?

An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.

ADRO AMED ACIU APTO

Zacks Equity Research

What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.

TNDM MASI ADRO ACIU

Zacks Equity Research

What Makes AC Immune (ACIU) a New Buy Stock

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACIU

Zacks Equity Research

AC Immune Enters Oversold Territory

AC Immune SA (ACIU) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ACIU

Zacks Equity Research

Roche Halts Two Late-Stage Studies on Alzheimer's Candidate

Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.

MRK RHHBY JNJ ACIU

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for January 25th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 25th:

CAPL ACIU ABMD

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for January 23rd

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:

BEAT ACIU ABMD

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for January 22nd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd:

SMPL GCO CHKE ACIU

Zacks Equity Research

Moving Average Crossover Alert: AC Immune

AC Immune SA (ACIU) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

ACIU

Zacks Equity Research

Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher

Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.

STML ACIU

Zacks Equity Research

Biogen Inks Two Deals to Make Drugs for Neurological Diseases

Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.

PFE LLY BIIB ACIU

Zacks Equity Research

Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug

Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.

JNJ LLY MRK ACIU

Zacks Equity Research

AC Immune (ACIU) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in AC Immune SA (ACIU).

ACIU

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for November 21st

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st:

AEE ACIW ACIU

Zacks Equity Research

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 30.77% and 36.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

ACIU

Zacks Equity Research

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACIU

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 13.04% and 5.78%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

ACIU

Zacks Equity Research

What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?

On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.

BDSI PBYI ACIU DNLI

Zacks Equity Research

What's in the Cards for Inovio (INO) This Earnings Season?

During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.

BDSI INO ACIU DNLI